Current status of stem cell transplantation for multiple myeloma

Current Treatment Options in Oncology

Volumn 6, Issue 3, 2005, Pages 229-240

  Gertz, Morie A ^a   Lacy, Martha Q ^b   Dispenzieri, Angela ^b   Hayman, Suzanne ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; BUSULFAN; CC 5103; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; IDARUBICIN; INTERFERON; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ANOREXIA; APATHY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEMENTIA; DEPRESSION; DIET; DISEASE EXACERBATION; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; FATIGUE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; LIFESTYLE; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PATIENT CARE; PERIPHERAL NEUROPATHY; PROTEINURIA; REVIEW; SOMNOLENCE; STANDARDIZATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 21744458837     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0006-1     Document Type: Review

References (55)

1. Gulbrandsen N, Wisloff F, Brinch L, et al.: Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001, 18:65-77.
2. Badros A, Barlogie B, Siegel E, et al.: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001, 114:600-607.
3. Badros A, Barlogie B, Siegel E, et al.: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822-829.
4. Moreau P, Misbahi R, Milpied N, et al.: Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia 2002, 16:1838-1843.
5. Le Blanc R, Montminy-Metivier S, Belanger R, et al.: Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001, 28:841-848.
6. Imrie K, Esmail R, Meyer RM, et al.: The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 2002, 136:619-629.
7. Attal M, Harousseau JL: Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol 2001, 38:226-230.
8. Child JA, Morgan GJ, Davies FE, et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
9. Vesole DH, Simic A, Lazarus HM: Controversy in multiple myeloma transplants: tandem autotransplants and miniallografts. Bone Marrow Transplant 2001, 28:725-735.
10. Lenhoff S, Hjorth M, Holmberg E, et al.: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000, 65:7-11.
11. Palumbo A, Triolo S, Argentino C, et al.: Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 1999, 94:1248-1253.
12. Blade J, Sureda A, Ribera JM, et al.: High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy: results of a prospective randomized trial from the Spanish cooperative group PETHEMA [abstract]. Blood 2001, 98:815a.
13. Fermand J-P, Ravaud P, Katsahian S, et al.: High-dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age [abstract]. Blood 1999, 94(Suppl 1):396a.
14. Schenkein DP, Koc Y, Alcindor T, et al.: Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor. Biol Blood Marrow Transplant 2000, 6:448-455.
15. Worel N, Greinix H, Ackermann J, et al.: Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol 2001, 80:345-348.
16. Tricot G, Spencer T, Sawyer J, et al.: Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002, 116:211-217.
17. Rajkumar SV, Fonseca R, Dispenzieri A, et al.: Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000, 26:979-983.
18. Alexanian R, Weber D, Giralt S, et al.: Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001, 27:1037-1043.
19. Morineau N, Tang XW, Moreau P, et al.: Lack of benefit of CD34+ cell selected over nonselected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study. Leukemia 2000, 14:1815-1820.
20. Barbui AM, Galli M, Dotti G, et al.: Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002, 116:202-210.
21. Segeren CM, Sonneveld P, van der Holt B, et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase III study. Blood 2003, 101:2144-2151.
22. Cavo M, Tosi P, Zamagni E, et al.: The "Bologna 96" clinical trial of single versus double autotransplant for previously untreated multiple myeloma patients [abstract]. Blood 2002, 100:179a.
23. Fermand J-P, Marolleau J-P, Alberti C, et al.: In single versus tandem high-dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) [abstract]. Blood 2001, 98:815a.
24. Rajkumar SV, Kyle RA, Gertz MA: Myeloma and the newly diagnosed patient: a focus on treatment and management. Semin Oncol 2002, 29(Suppl 17):5-10.
25. Perea G, Sureda A, Martino R, et al.: Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001, 80:592-587.
26. Morgan AE, Smith WK, Levenson JL: Reversible dementia due to thalidomide therapy for multiple myeloma. N Engl J Med 2003, 348:1821-1822.
27. Yakoub-Agha I, Attal M, Dumontet C, et al.: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002, 3:185-192.
28. Rajkumar SV, Hayman S, Gertz MA, et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 20:4319-4323.
29. Alexanian R, Weber D, Giralt S, Delasalle K: Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002, 13:1116-1119.
30. Rajkumar SV, Gertz MA, Lacy MQ, et al.: Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003, 17:775-779.
31. Harousseau JL: High-dose therapy in multiple myeloma. Ann Oncol 2002, 13(Suppl 4):49-54.
32. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002, 99:731-735.
33. Kumar A, Loughran T, Alsina M, et al.: Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003, 4:293-304.
34. Maloney DG, Molina AJ, Sehebi F, et al.: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003.
35. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR: Current therapy for multiple myeloma. Mayo Clin Proc 2002, 77:813-822.
36. Boccadoro M, Palumbo A, Bringhen S, et al.: Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002, 87:846-850.
37. Kazmi MA, Ahsan G, Schey SA: The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma. Clin Lab Haematol 2001, 23:125-129.
38. Watts MJ, Ings SJ, Flyn M, et al.: Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br J Haematol 2000, 111:287-291.
39. Morris CL, Siegel E, Barlogie B, et al.: Mobilization of CD34+ cells in elderly patients (greater than or equal to 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003, 120:413-423.
40. Demirer T, Ayli M, Ozcan M, et al.: Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002, 116:468-474.
41. Desikan KR, Tricot G, Munshi NC, et al.: Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001, 112:242-247.
42. Galimberti S, Morabito F, Guerrini F, et al.: Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003, 120:405-412.
43. Sirohi B, Powles R, Mehta J, et al.: The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med Oncol 2001, 18:39-50.
44. Shimoni A, Smith TL, Aleman A, et al.: Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001, 27:821-828.
45. Gertz MA, Lacy MQ, Inwards DJ, et al.: Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000, 26:45-50.
46. Porrata LF, Gertz MA, Inwards DJ, et al.: Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001, 98:579-585.
47. Gahrton G, Svensson H, Cavo M, et al.: Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209-216.
48. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18:3031-3037.
49. Kyle RA: Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. Clin Lymphoma 2001, 2:21-28.
50. Martinelli G, Terragna C, Zamagni E, et al.: Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000, 85:930-934.
51. Bensinger WI: Allogeneic hematopoietic cell transplantation for multiple myeloma. Biomed Pharmacother 2002, 56:133-138.
52. Lee CK, Badros A, Barlogie B, et al.: Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003, 31:73-80.
53. Kroger N, Schwerdtfeger R, Kiehl M, et al.: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete-remission rate in multiple myeloma. Blood 2002, 100:755-760.
54. Bellucci R, Alyea EP, Weller E, et al.: Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002, 99:4610-4617.
55. Kroger N, Kruger W, Renges H, et al.: Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001, 112:421-423.